share_log

8-K: Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

8-K: Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

8-K：Cingulate公佈2024年第一季度財務業績並提供臨床和業務最新情況
美股sec公告 ·  05/08 07:13
Moomoo AI 已提取核心訊息
On May 8, 2024, Cingulate Inc., a biopharmaceutical company, announced its financial results for the first quarter of 2024. The company, which specializes in Precision Timed Release™ drug delivery technology, reported a net loss of $3.0 million for the quarter, a decrease from the $4.0 million loss in the same period of the previous year. This reduction in net loss was attributed to decreased research and development (R&D) and general and administrative (G&A) expenses. R&D expenses dropped due to increased clinical activity offset by lower manufacturing and personnel costs, while G&A expenses fell primarily due to reduced personnel and insurance expenses. Cingulate also highlighted the progress of CTx-1301, its lead product candidate for the treatment of ADHD, which is on track...Show More
On May 8, 2024, Cingulate Inc., a biopharmaceutical company, announced its financial results for the first quarter of 2024. The company, which specializes in Precision Timed Release™ drug delivery technology, reported a net loss of $3.0 million for the quarter, a decrease from the $4.0 million loss in the same period of the previous year. This reduction in net loss was attributed to decreased research and development (R&D) and general and administrative (G&A) expenses. R&D expenses dropped due to increased clinical activity offset by lower manufacturing and personnel costs, while G&A expenses fell primarily due to reduced personnel and insurance expenses. Cingulate also highlighted the progress of CTx-1301, its lead product candidate for the treatment of ADHD, which is on track for a Marketing Approval filing with the FDA in the first half of 2025. The company raised $10.7 million in capital and converted $3.3 million of debt to equity in 2024. As of March 31, 2024, Cingulate had $1.1 million in cash and cash equivalents, with total liabilities decreasing to $2.3 million and stockholders' equity increasing by $10 million to $3.2 million.
2024年5月8日，生物製藥公司Cingulate Inc. 公佈了其2024年第一季度的財務業績。該公司專門從事Precision Timed Release™ 藥物遞送技術，報告本季度淨虧損300萬美元，低於去年同期的400萬美元虧損。淨虧損的減少歸因於研發（R&D）以及一般和管理（G&A）支出的減少。研發費用下降是由於臨床活動的增加被較低的製造和人員成本所抵消，而G&A支出下降的主要原因是人員和保險費用的減少。Cingulate還強調了其治療注意力缺陷多動障礙的主要候選產品CTx-1301的進展，該產品有望在2025年上半年向美國食品藥品管理局申請上市許可。該公司在2024年籌集了1,070萬澳元的資本，並將330萬澳元的債務轉換爲股權。截至2024年3月31日，Cingulate擁有110萬美元的現金及現金等價物，總負債減少至230萬美元，股東權益增加了1000萬美元，至320萬美元。
2024年5月8日，生物製藥公司Cingulate Inc. 公佈了其2024年第一季度的財務業績。該公司專門從事Precision Timed Release™ 藥物遞送技術，報告本季度淨虧損300萬美元，低於去年同期的400萬美元虧損。淨虧損的減少歸因於研發（R&D）以及一般和管理（G&A）支出的減少。研發費用下降是由於臨床活動的增加被較低的製造和人員成本所抵消，而G&A支出下降的主要原因是人員和保險費用的減少。Cingulate還強調了其治療注意力缺陷多動障礙的主要候選產品CTx-1301的進展，該產品有望在2025年上半年向美國食品藥品管理局申請上市許可。該公司在2024年籌集了1,070萬澳元的資本，並將330萬澳元的債務轉換爲股權。截至2024年3月31日，Cingulate擁有110萬美元的現金及現金等價物，總負債減少至230萬美元，股東權益增加了1000萬美元，至320萬美元。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息